{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=51", "query": { "intervention": "Active capsule", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 1419, "total_pages": 142, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+capsule&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T04:58:29.507Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04729595", "title": "Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Tempol", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Adamis Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2021-09-01", "completion_date": "2022-09-21", "has_results": false, "last_update_posted_date": "2022-12-06", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 17, "location_summary": "Anniston, Alabama • Los Angeles, California • Doral, Florida + 13 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729595" }, { "nct_id": "NCT05668754", "title": "Study of SDX in Patients With Idiopathic Hypersomnia (IH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Hypersomnia" ], "interventions": [ { "name": "Serdexmethylphenidate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Zevra Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-12-28", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Guntersville, Alabama + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668754" }, { "nct_id": "NCT02706951", "title": "A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo Upadacitinib", "type": "DRUG" }, { "name": "Placebo Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 648, "start_date": "2016-03-23", "completion_date": "2022-08-10", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 52, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706951" }, { "nct_id": "NCT01854645", "title": "Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "GFF MDI", "type": "DRUG" }, { "name": "GP MDI", "type": "DRUG" }, { "name": "FF MDI", "type": "DRUG" }, { "name": "Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)", "type": "DRUG" }, { "name": "Placebo MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 2103, "start_date": "2013-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 121, "location_summary": "Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854645" }, { "nct_id": "NCT04828551", "title": "Noninvasive Biomarkers of Metabolic Liver Disease 1.1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nonalcoholic Steatohepatitis", "Nonalcoholic Fatty Liver" ], "interventions": [ { "name": "Ultrasound based shear wave speed and fat quantification methods", "type": "DEVICE" }, { "name": "Blood collection", "type": "DIAGNOSTIC_TEST" }, { "name": "Physical measurements", "type": "OTHER" }, { "name": "Clinical history and medication reviews", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-03-18", "completion_date": "2021-11-20", "has_results": true, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 2, "location_summary": "San Diego, California • Boston, Massachusetts", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04828551" }, { "nct_id": "NCT00249301", "title": "A Study of MLN8054 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasm", "Colon Neoplasm", "Pancreatic Neoplasm", "Bladder Neoplasm" ], "interventions": [ { "name": "MLN8054", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-04-01", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249301" }, { "nct_id": "NCT07766499", "title": "A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria (CSU)", "Chronic Idiopathic Urticaria" ], "interventions": [ { "name": "THB335 Lower Dose", "type": "DRUG" }, { "name": "THB335 Higher Dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calixis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 81, "start_date": "2026-09-15", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 15, "location_summary": "Pasadena, California • Ventura, California • Walnut Creek, California + 12 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07766499" }, { "nct_id": "NCT03900793", "title": "Losartan + Sunitinib in Treatment of Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteosarcoma" ], "interventions": [ { "name": "Losartan", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 41, "start_date": "2019-08-26", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03900793" }, { "nct_id": "NCT01090414", "title": "An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2010-03-22", "completion_date": "2018-06-18", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090414" }, { "nct_id": "NCT00579436", "title": "Effects of Fish Oils on Inflammation and Insulin Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metabolic Syndrome", "Insulin Resistance" ], "interventions": [ { "name": "omega-3 fatty acid", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philip Kern", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 33, "start_date": "2007-01", "completion_date": "2015-01-15", "has_results": true, "last_update_posted_date": "2018-05-16", "last_synced_at": "2026-11-03T04:58:29.507Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00579436" } ] }